106047-29-4

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Bromo-2-(pyridin-4-yl)pyridine is used as a chemical intermediate for the synthesis of complex pharmaceutical compounds. Its unique structure allows for the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Research and Development:
In the agrochemical industry, 6-Bromo-2-(pyridin-4-yl)pyridine is employed as a chemical intermediate in the development of new agrochemical products, such as pesticides and herbicides. Its role in the synthesis of these compounds contributes to the advancement of agricultural technologies and crop protection strategies.
Used in Laboratory Research Settings:
6-Bromo-2-(pyridin-4-yl)pyridine is utilized as a research compound in various laboratory experiments, where it can be used to study chemical reactions, mechanisms, and properties. Its versatility as a chemical intermediate makes it a valuable tool for scientists working in diverse research areas.

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 93830-58-1 diethyl (pyridin-4-yl)borane 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1313590-70-3 N-(3-methylphenyl)-6-(4-pyridinyl)-2-pyridinamine 
• 1191076-26-2 C₁₆H₁₁BrN₂ 

Relevant academic research and scientific papers

NOVEL COMPOUND WITH ELECTRON INJECTION AND/OR ELECTRON TRANSPORT CAPABILITIES AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Formula 1 Substituents in Formula 1 are the same as defined in the specification.

CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE CONDENSED-CYCLIC COMPOUND

A condensed-cyclic compound and an organic light-emitting diode including the condensed-cyclic compound.

Organic light emitting device containing polycyclic heteroaryl compounds

A heterocyclic compound of general formula (1), an organic light-emitting device including the heterocyclic compound,and a flat panel display device including the organic light-emitting device are provided. The organic light-emitting devices using the heterocyclic compounds have high-efficiency, low driving voltage, high luminance and long lifespan: in which for example R4, R5, R6, R7, R8, R10 and R11 are hydrogen atoms, R1 and R9 are non-hydrogen substituent, and R2 and R3 are selected from methyl and phenyl groups.

Phenanthro[2,3-b]pyrroles and Phenanthro[3,2-b]pyrroles for organic light-emitting devices

Embodiments of the present invention are directed to a heterocyclic compound and an organic light-emitting device including the heterocyclic compound. The organic light-emitting devices using the heterocyclic compounds have high-efficiency, low driving vo

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells

We recently identified a class of pyridyl aniline thiazoles (PAT) that displayed selective cytotoxicity for von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC) cells in vitro and in vivo. Structure-activity relationship (SAR) studies were used to develop a comparative molecular field analysis (CoMFA) model that related VHL-selective potency to the three-dimensional arrangement of chemical features of the chemotype. We now report the further molecular alignment-guided exploration of the chemotype to discover potent and selective PAT analogues. The contribution of the central thiazole ring was explored using a series of five- and six-membered ring heterocyclic replacements to vary the electronic and steric interactions in the central unit. We also explored a positive steric CoMFA contour adjacent to the pyridyl ring using Pd-catalysed cross-coupling Suzuki-Miyaura, Sonogashira and nucleophilic displacement reactions to prepare of a series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively. In vitro potency and selectivity were determined using paired RCC cell lines: the VHL-null cell line RCC4 and the VHL-positive cell line RCC4-VHL. Active analogues selectively induced autophagy in RCC4 cells. We have used the new SAR data to further develop the CoMFA model, and compared this to a 2D-QSAR method. Our progress towards realising the therapeutic potential of this chemotype as a targeted cytotoxic therapy for the treatment of RCC by exploiting the absence of the VHL tumour suppressor gene is reported.

Bipyridine-based compound and organic light emitting diode employing organic layer comprising the same

The invention is directed to bipyridine-based compounds and organic light emitting diodes (OLED) including organic layers comprising the bipyridine-based compound. OLEDs including organic layers comprising the bipyridine-based compounds have low driving voltages, high current densities, high efficiencies and long lifetimes.

Substituted pyridine and pyridazine compounds and methods of use

Selected novel substituted pyridine and pyridazine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.